Information Systems Review (경영정보학연구)

The Korea Society of Management Information Systems (한국경영정보학회)
권호 표지
DOI QR코드

DOI QR Code

The Information Effect of FDA Approval Announcements on Pharmaceutical and Bio-Health Companies' Stock Prices

FDA 승인 공시가 제약 및 바이오·헬스케어 기업의 주가에 미치는 정보효과

  • Yu Jeong Song (Sogang Business School, Sogang University) ;
  • Sang-Gun Lee (Sogang Business School, Sogang University) ;
  • So Ra Park (Department of Business, Chonnam National University)
  • Received : 2023.12.13
  • Accepted : 2024.02.09
  • Published : 2024.02.29
Download PDF
⟨ Previous Next ⟩

Abstract

Korean pharmaceutical and bio-health companies began applying for FDA approval in 2000. However, drug companies in South Korea are not required to obtain FDA approval to market their products on the South Korean market, and the approval process is highly resource-intensive. This study utilizes event study methodology to examine the information effect of US FDA approval announcements on the stock prices of pharmaceutical and bio-health companies listed on South Korean stock markets. The study's results show that FDA approval announcements caused abnormal increases in corporate stock prices, indicating that these announcements have a transnational information effect on South Korean companies' value. Furthermore, the results show that the impact of FDA approval announcements on stock prices is greater for small companies than mid-sized and large companies and in bio and healthcare industries than in the traditional pharmaceutical industry. This impact is also more significant on the KOSDAQ (Korea Securities Dealers Automated Quotation) companies than the KOSPI (Korean Composite Stock Price Index) companies and after the expansion of stock price limits. These findings signal that the information effect is more significant when regulatory controls are weaker. The results also indicate that obtaining FDA approval brings above-normal returns for companies and that FDA application is a high-risk, high-return investment.

한국의 제약 및 바이오·헬스케어 기업들은 2000년대 초부터 FDA 승인을 신청하기 시작했다. 제약회사들은 국내 시장에서 제품을 판매하기 위해 의무적으로 FDA 승인을 받을 필요가 없으며, 승인 과정에 있어 많은 자원을 필요로 한다. 따라서 FDA 승인을 받기위한 투자는 합리적으로 보이지 않는다. 본 연구는 사건연구(event study) 방법론을 활용하여 유가증권 시장 및 코스닥 시장에 상장된 제약 및 바이오·헬스케어 기업들의 주가에 대한 FDA 승인 공시의 정보 효과를 분석하였다. 연구 분석결과에 따르면, FDA 승인 공시에 대한 정보효과가 한국 주식 시장에서 작동하여 해당 기업의 주가를 유의하게 상승시키는 것으로 나타났다. 이는 미국 FDA 승인이 한국 제약 및 바이오·헬스케어 기업의 가치를 제고시키는 효과가 있다는 것을 시사한다. 또한, 중견 및 대기업보다는 중소기업에서, 코스피 시장보다는 코스닥 시장에서, 주가의 가격제한폭이 좁을 때 보다는 확대된 이후에 주가에 정보효과가 더 크게 반영되어 나타났다. 그리고 전통적인 제약산업보다는 바이오·헬스케어 산업인 경우, FDA 승인 공시에 주가는 더 민감하게 반응하는 것을 알 수 있다. 이상의 결과를 토대로 FDA 승인을 얻는 것이 기업의 주가에 긍정적 영향을 미친다는 것을 알 수 있었으며, 국내 기업들의 FDA 승인 신청이 고위험을 감수하며 높은 수익을 노리는 합리적인 투자에 해당함을 제시한다.

Keywords

Acknowledgement

이 논문은 전남대학교 학술연구비 지원에 의하여 연구되었음(과제번호: 2023-0491).

References

  1. Ahn, B. J. and M. Kim, "Hironic's acne treating laser device approved by FDA", PULSE by Maeil Business News Korea, 2018.09.18., Available at https://pulsenews.co.kr/view.php?year=2018&no=588630.
  2. Ajinkya, B. B. and M. J. Gift, "Corporate managers' earnings forecasts and symmetrical adjustments of market expectations", Journal of Accounting Research, 1984, pp. 425-444.
  3. Aparicio, V., D. S. Gordon, G. Huayamares, and Y. Luo, "BioFinBERT: Finetuning Large Language Models (LLMs) to Analyze Sentiment of Press Releases and Financial Text Around Inflection Points of Biotech Stocks", arXiv preprint, Vol.arXiv:2401.11011, 2024, Available at https://arxiv.org/ftp/arxiv/papers/2401/2401.11011.pdf. 1011.pdf
  4. Arbel, A., S. Carvell, and P. Strebel, "Giraffes, institutions and neglected firms", Financial Analysts Journal, Vol.39, No.3, 1983, pp. 57-63., https://doi.org/10.2469/faj.v39.n3.57.
  5. Baccardax, M., "Gilead Sciences jumps higher after FDA gives Coronavirus treatment 'orphan drug' Status", TheStreet, 2020.03.24., Available at https://www.thestreet.com/investing/gilead-gets-fda-orphan-drug-status-for-coronavirus-treatment.
  6. Ball, R. and P. Brown, "An empirical evaluation of accounting income numbers", Financial Accounting and Equity Markets, Routledge, 2013. pp. 27-46.
  7. Bang, J. W., J. S. Kim, M. B. Lee, and S. H. Kim, "The Impact of ERP Implementation Announcement on the Market Value of the Firm", Asia Pacific Journal of Information Systems, Vol.11, No.3, 2001, pp. 185-208.
  8. Barry, C. B. and S. J. Brown, "Differential information and the small firm effect", Journal of Financial Economics, Vol.13, No.2, 1984, pp. 283-294, https://doi.org/10.1016/0304-405X(84)90026-6.
  9. Bohmann, M. J. and V. Patel, "Informed options trading prior to FDA announcements", Journal of Business Finance and Accounting, Vol.49, No.7-8, 2022, pp. 1211-1236, https://doi.org/10.1111/jbfa. 12600.
  10. Bosch, J. C. and I. Lee, "Wealth effects of Food and Drug Administration (FDA) decisions", Managerial and Decision Economics, Vol.15, No.6, 1994, pp. 589-599. https://doi.org/10.1002/mde.4090150606
  11. Brown, S. J. and J. B. Warner, "Using daily stock returns: The case of event studies", Journal of Financial Economics, Vol.14, No.1, 1985, pp. 3-31. https://doi.org/10.1016/0304-405X(85)90042-X
  12. Budennyy, S., A. Kazakov, E. Kovtun, and L. Zhukov, "New drugs and stock market: how to predict pharma market reaction to clinical trial announcements", arXiv Scholarly Paper, 2022, Available at http://arxiv.org/abs/2208.07248.
  13. Bursztynsky, J. and L. Kolodny, "Tesla stock closes down more than 12% after Musk's Twitter deal", CNBC, 2022.04.26, Available at https://www.cnbc.com/2022/04/26/tesla-stock-falls-more-than-9percent-after-musks-twitter-deal.html.
  14. Chacko, G., P. Tufano, and G. Verter, "Cephalon, Inc. Taking risk management theory seriously", Journal of Financial Economics, Vol.60, No.2-3, 2001, pp. 449-485. https://doi.org/10.1016/S0304-405X(01)00050-2
  15. Chan, S. H., J. W. Kensinger, A. J. Keown, and J. D. Martin, "Do strategic alliances create value?", Journal of Financial Economics, Vol.46, No.2, 1997, pp. 199-221, https://doi.org/10.1016/S0304-405X(97)00029-9.
  16. Chan, S. H., J. D. Martin, and J. W. Kensinger, "Corporate research and development expenditures and share value", Journal of Financial Economics, Vol.26, No.2, 1990, pp. 255-276, https://doi.org/10.1016/0304-405X(90)90005-K.
  17. Chaney, P. K., T. M. Devinney, and R. S. Winer, "The impact of new product introductions on the market value of firms", Journal of Business, 1991, pp. 573-610.
  18. Chen, Y. J., Z. Y. Feng, Y. P. Li, and H. W. Huang, "The economic consequences of US FDA new drug approvals: Evidence from Taiwan pharmaceutical and biotech companies", Innovation, Vol.23, No.3, 2021, pp. 354-374. https://doi.org/10.1080/14479338.2020.1786389
  19. Chen, Z., D. S. Dhaliwal, and H. Xie, "Regulation fair disclosure and the cost of equity capital", Review of Accounting Studies, Vol.15, 2010, pp. 106-144, https://doi.org/10.1007/s11142-009-9115-6.
  20. Cho, H. S., "Global Competition in Pharmaceutical- and Bio-technology and Korea's Strategy", Journal of Social Science, Vol.62, No.2, 2023, pp. 137-158, https://doi.org/10.22418/ JSS.2023.4.62.2.137.
  21. Clifford, C., "How the Moderna Covid-19 mRNA vaccine was made so quickly", CNBC, 2021.07.03., Available at https://www.cnbc.com/2021/07/03/how-moderna-made-its-mrna-covid-vaccine-so-quickly-'noubar-afeyan.html.
  22. Congressional Budget Office, "Research and development in the pharmaceutical industry", 2021, Available at https://www.cbo.gov/publication/57126.
  23. Dambra, M., B. Schonberger, and C. Wasley, "Creating visibility: Voluntary disclosure by private firms pursuing an initial public offering", Review of Accounting Studies, 2023, pp. 1-50, https://doi.org/10.1007/s11142-023-09763-y.
  24. DiMasi, J. A., H. G. Grabowski, and R. W. Hansen, "Innovation in the pharmaceutical industry: new estimates of RandD costs", Journal of Health Economics, Vol.47, 2016, pp. 20-33, https://doi.org/10.1016/j.jhealeco.2016.01.012.
  25. Ding, L., H. K. Lam, T. C. E. Cheng, and H. Zhou, "A review of short-term event studies in operations and supply chain management", International Journal of Production Economics, Vol.200, 2018, pp. 329-342, https://doi.org/10.1016/j.ijpe.2018.04.006.
  26. Fama, E. F., "Perspectives on October 1987, or, what did we learn from the crash?", Center for Research in Security Prices, Graduate School of Business, University of Chicago, 1988.
  27. Fama, E. F., L. Fisher, M. C. Jensen, and R. Roll, "The adjustment of stock prices to new information", International Economic Review, Vol.10, No.1, 1969, pp. 1-21. https://doi.org/10.2307/2525569
  28. Galkina Cleary, E., J. M. Beierlein, N. S. Khanuja, L. M. McNamee, and F. D. Ledley, "Contribution of NIH funding to new drug approvals 2010- 2016", Proceedings of the National Academy of Sciences, Vol.115, No.10, 2018, pp. 2329-2334. https://doi.org/10.1073/pnas.1715368115
  29. Gigante, G., A. Cerri, and G. Leone, "The impact of mergers and acquisitions on shareholders' value: an empirical study of pharmaceutical companies", Managerial Finance, 2023, https://doi.org/10.1108/MF-01-2022-0015.
  30. Gunn, M., "When an FDA drug approval makes mainstream news: The announcement of zulresso, a media case study", Journal of Commercial Biotechnology, Vol.24, No.4, 2019.
  31. Hamill, P. A., M. Hutchinson, Q. M. N. Nguyen, and M. Mulcahy, "FDA approval announcements: Attention-grabbing or event-day misspecification?", Economics Letters, Vol.170, 2018, pp. 171-174, https://doi.org/10.1016/j.econlet.2018.06.024.
  32. Hsiao, Y. C. and M. H. Wu, "Does Partner Asymmetry Facilitate Innovation Speed? Organizational Learning and Social Exchange Perspectives", IEEE Transactions on Engineering Management, 2022, https://doi.org/10.1109/TEM.2022.3228562.
  33. Ibrahim, S., "Comparing FDA and EMA decisions for market authorization of generic drug applications covering 2017-2020", Office of Generic Drugs, 2022.
  34. IQVIA, "The changing landscape of research and development", 2019, Available at https://www.iqvia.com/insights/the-iqvia-institute/reports/the-changing-landscape-of-research-and-development.
  35. Ivanov, P. C., A. Yuen, and P. Perakakis, "Impact of stock market structure on intertrade time and price dynamics", PLoS One, Vol.9, No.4, 2014, p. e92885, https://doi.org/10.1371/journal.pone.0092885.
  36. Javid, A. Y. and H. Malik, "Performance and capital structure of IPOs in Pakistan from 2000 to 2015", Financial Innovation, Vol.2, 2016, pp. 1-19, https://doi.org/10.1186/s40854-016-0032-y.
  37. Jeong, A. Y. and J. H. Lim, "The impact of blockchain technology adoption announcements on firm's market value", Journal of Information Systems, Vol.37, No.1, 2023, pp. 39-65, https://doi.org/10.2308/ISYS-2021-038.
  38. Ji, P. and G. Yu, "Preemptive or Catch Up? Performance Differences under Enterprise Digital Transformation", Asia Pacific Journal of Information Systems, Vol.32, No.3, 2022, pp. 564-579, https://doi.org/ 10.14329/apjis.2022.32.3.564.
  39. Khan, F. A., "Biotechnology Fundamentals Third Edition", CRC Press, 2020.
  40. Kim, B. and E. Lee, "U.S. FDA approves Celltrion's HIV-1 treatment", PULSE by Maeil Business News Korea, 2018.11.19., Available at https://pulsenews.co.kr/view.php?year=2018andno=724614.
  41. Kim, M. S., "How to Build South Korean Bio-Medical Industry's Competitive Force," DigitalBizOn. 2022.05.25., Available at http://www.digitalbizon.com/news/articleView.html?idxno=2330334.
  42. Kliger, D., T. Rothman, and S. Mousavi, "Pharmaceutical Lottery Stocks: Investors' Reaction to FDA Announcements", 2021, Available at https://doi.org/10.2139/ssrn.3911774.
  43. Korea Biomedicine Industry Association, "Strategic information for global market penetration of biomedical drugs", 2018, Available at https://www.kobia.kr/bbs/board.php?tbl=notice&mode=VIEW&num=173.
  44. Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Pharmaceutical industry data book, 2019, Available at https://www.kpbma.or.kr/library/publications/list?b_category=2&start=0&search_txt=.
  45. Kwon, H. and H. Lee, "The Impact of Alliance on Market Value of the Bio-pharmaceutical Firm in Korea", Journal of the Korea Academia-Industrial Cooperation Society, Vol.18, No.7, 2017, pp. 149-161, https://doi.org/10.5762/KAIS.2017.18.7.149.
  46. Kwon, S. M. and C. H. Han, "Empirical investigation on information breach effect on the market value of the firm: Focused on source and long term performance", Journal of Society for e-Business Studies, Vol.21, No.2, 2017, https://doi.org/10.7838/jsebs.2016.21.2.081.
  47. Kyle, A. S., "Trading halts and price limits", Review of Futures Markets, Vol.7, No.3, 1988, pp. 426-434.
  48. Lee, E. and N. Hyung, "Widening price limit effects on volatility: Using portfolio return and EGARCH Model. The Korean Data Analysis Society", Journal of The Korean Data Analysis Society, Vol.24, No.6, 2022, pp. 2229-2246. https://doi.org/10.37727/jkdas.2022.24.6.2229.
  49. Lee, H. S., "Successive failures throw Korean bioindustry's drug-developing ability into question", Korea Biomedical Review, 2019.09.26., Available at http://www.koreabiomed.com/news/articleView.html?idxno=6509.
  50. Lee, H. S., "Successive failures throw Korean bioindustry's drug-developing ability into question", Korea Biomedical Review, 2019.09.26., Available at http://www.koreabiomed.com/news/articleView.html?idxno=6509.
  51. Lee, S. M., Y. Noh, D. Choi, and S. J. Rha, "The effect of ISO 14001 on equity structure", Industrial Management and Data Systems, Vol.114, No.6, 2014, pp. 979-991, https://doi.org/10.1108 /IMDS-01-2014-0021. https://doi.org/10.1108/IMDS-01-2014-0021
  52. Lin, C., R. Morck, B. Yeung, and X. Zhao, "What do we learn from stock price reactions to China's first announcement of anti-corruption reforms?", The Journal of Finance and Data Science, Vol.9, 2023, 100096, https://doi.org/10.1016/j.jfds.2023.100096.
  53. Lo, A. W. and R. T. Thakor, "Financial intermediation and the funding of biomedical innovation: A review", Journal of Financial Intermediation, 2023, 101028, https://doi.org/10.1016/j.jfi.2023.101028.
  54. Ma, C. K., R. P. Rao, and S. Sears, "Limit moves and price resolution: The case of the treasury bond futures market", The Journal of Futures Markets (1986-1998), Vol.9, No.4, 1989, pp. 321.
  55. MacKinlay, A. C., "Event studies in economics and finance", Journal of Economic Literature, Vol.35, No.1, 1997, pp. 13-39.
  56. Masulis, R. W. and L. Shivakumar, "Does market structure affect the immediacy of stock price responses to news?", Journal of Financial and Quantitative Analysis, Vol.37, No.4, 2002, pp. 617-648, https://doi.org/10.2307/3595014.
  57. Mathur, L. K., I. Mathur, and N. Rangan, "The wealth effects associated with a celebrity endorser: The Michael Jordan phenomenon", Journal of Advertising Research, Vol.37, No.3, 1997, pp. 67-74.
  58. Mc Namara, P. and C. Baden-Fuller, "Shareholder returns and the exploration-exploitation dilemma: RandD announcements by biotechnology firms", Research Policy, Vol.36, No.4, 2007, pp. 548-565, https://doi.org/10.1016/j.respol.2007.02.012.
  59. McWilliams, A. and D. Siegel, "Event studies in management research: Theoretical and empirical issues", Academy of Management Journal, Vol.40, No.3, 1997, pp. 626-657, https://doi.org/10.5465/257056.
  60. Petrov, E., and S. Schantl, "Conversations Between Managers and Investors", 2023, https://doi.org/10.2139/ssrn.4412167.
  61. Rasoulian, S., Y. Gregoire, R. Legoux, and S. Senecal, "The effects of service crises and recovery resources on market reactions: An event study analysis on data breach announcements", Journal of Service Research, Vol.26, No.1, 2023, pp. 44-63, https://doi.org/10.1177/10946705211036944.
  62. Reddy, K., M. Qamar, and N. Yahanpath, "Do mergers and acquisitions create value? The post-MandA performance of acquiring firms in China and India", Studies in Economics and Finance, Vol.36, No.2, 2019, pp. 240-264, https://doi.org/10.1108/SEF-01-2018-0027.
  63. Rennane, S., L. Baker, and A. Mulcahy, "Estimating the cost of industry investment in drug research and development: a review of methods and results", INQUIRY: The Journal of Health Care Organization, Provision, and Financing, Vol.58, 2021, 00469580211059731, https://doi.org/10.1177/00469580211059731.
  64. Ringel, M. S. and M. K. Choy, "Do large mergers increase or decrease the productivity of pharmaceutical RandD?", Drug Discovery Today, Vol.22, No.12, 2017, pp. 1749-1753, https://doi.org/10.1016/j.drudis.2017.06.002.
  65. Rothenstein, J. M., G. Tomlinson, I. F. Tannock, and A. S. Detsky, "Company stock prices before and after public announcements related to oncology drugs", Journal of the National Cancer Institute, Vol.103, No.20, 2011, pp. 1507-1512. https://academic.oup.com/jnci/article/103/20/1507/904625. 103/20/1507/904625
  66. Sarkar, S. K. and P. J. de Jong, "Market response to FDA announcements", The Quarterly Review of Economics and Finance, Vol.46, No.4, 2006, pp. 586-597, https://doi.org/10.1016/j.qref.2005.01.003.
  67. Sharma, A. and N. Lacey, "Linking product development outcomes to market valuation of the firm: The case of the US pharmaceutical industry", Journal of Product Innovation Management, Vol.21, No.5, 2004, pp. 297-308, https://doi.org/10.1111/j.0737-6782.2004.00084.x.
  68. Shin, Y. W., J. Y. Yun, H. J. Jeon, C. Y. Kim, J. H. Kim, and Y. R. Kim, "2020 Drug industry analysis report", Korea Health Industry Development Institute, 2021, Available at https://www.khidi.or.kr/board/view?linkId=48862776&menuId=MENU00085.
  69. Shkolnykova, M. and M. Kudic, "Who benefits from SMEs' radical innovations?empirical evidence from German biotechnology", Small Business Economics, Vol.58, No.2, 2022, pp. 1157-1185, https://doi.org/10.1007/s11187-021-00464-x.
  70. Simoens, S. and I. Huys, "How much do the public sector and the private sector contribute to biopharmaceutical RandD?", Drug Discovery Today, Vol.27, No.4, 2022, pp. 939-945, https://doi.org/10.1016/j.drudis.2021.11.027.
  71. Torabzadeh, K. M., C. G. Woodruff, and N. Sen, "FDA decisions on new drug applications and the market value of pharmaceutical firms", American Business Review, Vol.16, No.2, 1998, pp. 42-50.
  72. Tripathi, M. and A. Mukhopadhyay, "Financial loss due to a data privacy breach: An empirical analysis", Journal of Organizational Computing and Electronic Commerce, Vol.30, No.4, 2020, pp. 381-400, https://doi.org/10.1080/10919392.2020.1818521.
  73. Tweneboah-Kodua, S., F. Atsu, and W. Buchanan, "Impact of cyberattacks on stock performance: A comparative study", Information and Computer Security, Vol.26, No.5, 2018, pp. 637-652, https://doi.org/10.1108/ICS-05-2018-0060.
  74. Weinzimmer, L., C. A. Esken, E. J. Michel, W. C. McDowell, and R. V. Mahto, "The differential impact of strategic aggressiveness on firm performance: The role of firm size", Journal of Business Research, Vol.158, 2023, 113623, https://doi.org/10.1016/j.jbusres.2022.113623.
  75. Wu, Z., P. Borochin, and J. H. Golec, "Informed Options Trading Before FDA Drug Advisory Committee Meetings", University of Miami Business School Research Paper, 2021, 3825062, https://doi.org/10.2139/ssrn.3825062.
  76. Yashiro, K., Y. Lim, S. Sengoku, and K. Kodama, "Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries", Drug Discovery Today, 2022, 103483, https://doi.org/10.1016/j.drudis.2022.103483.
  77. Zhang, X., X. Li, J. Hao, and P. Li, "Price limit change and magnet effect: The role of investor attention", Finance Research Letters, Vol.53, 2023, 103577, https://doi.org/10.1016 /j.frl.2022.103577. https://doi.org/10.1016/j.frl.2022.103577